Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anxiety Disorders Therapy
Recent findings in anxiety disorders therapy described by researchers from University of Texas
May 21st, 2008
Researchers detail in 'Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine,' new data in anxiety disorders. "Most antidepressants in clinical use are believed to function by enhancing neurotransmission of serotonin [5-hydroxytryptamine (5-HT)] and/or norepinephrine (NE) via inhibition of neurotransmitter reuptake. Agents that affect reuptake of both 5-HT and NE (serotonin-norepinephrine reuptake inhibitors) have been postulated to offer greater efficacy for the treatment of major depressive disorder (MDD)," researchers in the United States report. "These dual-acting agents also display a broader spectrum of action, including efficacy for...
Source: Immunotherapy Weekly (2008-05-21)
|
